Skip to content
Buy This GLP
← Research
Evidence

GLP-1 vs SGLT2 Inhibitor: What the Heart Outcome Evidence Shows

Both drug classes reduced major cardiovascular events versus placebo in a review of people with diabetes and a prior heart attack. The class comparison was indirect.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
SGLT2 inhibitor against GLP-1 — all of it indirectmajor CV events7 studies: 2 vs 5heart failure admission6 studies: 2 vs 4heart attack4 studies: 1 vs 3These estimates come from separate placebo trials.

The best choice depends on the reason for treatment and the evidence for the specific medicine. Studies of GLP-1 drugs and heart attacks include several different populations. This review focused on people with type 2 diabetes and a history of heart attack [1].

What the comparison found

Against placebo, the hazard ratio for major cardiovascular events was 0.87 for SGLT2 inhibitors and 0.83 for GLP-1 drugs. The indirect comparison of SGLT2 inhibitors with GLP-1s gave 1.05 (95% CI 0.92 to 1.20) [1]. It did not establish a clear advantage for either class.

For heart failure admission, the indirect hazard ratio was 0.83 (95% CI 0.67 to 1.03). The estimate favored SGLT2 inhibitors, but the interval included no difference. Most studies included people whose heart attacks occurred well before enrollment. The findings are less directly applicable immediately after a heart attack.

How clinicians choose between the classes

The 2026 ADA and EASD consensus uses a person’s cardiovascular and kidney risk to guide treatment [2]. Our guide to taking a GLP-1 and an SGLT2 inhibitor together covers a third option clinicians may consider. The indirect class comparison above estimates outcomes for each class separately.

Heart failure, chronic kidney disease, weight goals and tolerability all affect that choice.

Frequently asked

Was the comparison between classes direct?
The review estimated the difference through separate placebo-controlled trials.
Did one class clearly reduce major cardiovascular events more?
The indirect hazard ratio was 1.05, with a 95% confidence interval of 0.92 to 1.20. It leaves uncertainty about which class had the larger benefit.
What factors guide the choice?
A clinician considers the reason for treatment, including heart failure, kidney disease, cardiovascular risk and weight-related goals.

Sources

  1. [1] Ren Y, et al. (2026). Cardiovascular outcomes of SGLT2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes and a history of myocardial infarction Frontiers in Endocrinology. PMID 42591121
  2. [2] American Diabetes Association and European Association for the Study of Diabetes (2026). Management of type 2 diabetes, 2026: a consensus report Diabetologia. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence